ReviewFrontiers in pharmacology2020
COVID-19 Usurps Host Regulatory Networks.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Guillain-Barré Syndrome After Inactivated Poliovirus Vaccination: A Rare Clinical Case Report.Annals of medicine and surgery (2012) · 2025Article
- Impact of various high fat diets on gene expression and the microbiome across the mouse intestines.Scientific reports · 2023Article
- Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model.Frontiers in immunology · 2023Article
- Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity.iScience · 2022Article
- SARS-CoV-2 and Skin: New Insights and Perspectives.Biomolecules · 2022Review
- Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity.Frontiers in immunology · 2022Observational
- Serum peptidome profiles immune response of COVID-19 Vaccine administration.Frontiers in immunology · 2022Article
- RAGE pathway activation and function in chronic kidney disease and COVID-19.Frontiers in medicine · 2022Review
- Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease.Frontiers in pharmacology · 2022Review
- Host Manipulation Mechanisms of SARS-CoV-2.Acta biotheoretica · 2021Article
- Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.Archives of medical research · 2021Review
- Problems of Pathogenesis and Pathogenetic Therapy of COVID-19 from the Perspective of the General Theory of Pathological Systems (General Pathological Processes).International journal of molecular sciences · 2021Review
- Obesity and its impact on COVID-19.Journal of molecular medicine (Berlin, Germany) · 2021Review
- ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients.The American journal of pathology · 2021Review
- Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.Journal of biomaterials science. Polymer edition · 2021Article
- Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing.PLoS pathogens · 2021Review
- Review
- Article
- Immunogenetic Association Underlying Severe COVID-19.Vaccines · 2020Review
- Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data.medRxiv : the preprint server for health sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 binds the angiotensin-converting enzyme 2 (ACE2) on the cell surface and this complex is internalized. ACE2 serves as an endogenous inhibitor of inflammatory signals associated with four major regulator systems: the renin-angiotensin-aldosterone system (RAAS), the complement system, the coagulation cascade, and the kallikrein-kinin system (KKS). Understanding the pathophysiological effects of SARS-CoV-2 on these pathways is needed, particularly given the current lack of proven, effective treatments. The vasoconstrictive, prothrombotic and pro-inflammatory conditions induced by SARS-CoV-2 can be ascribed, at least in part, to the activation of these intersecting physiological networks. Moreover, patients with immune deficiencies, hypertension, diabetes, coronary heart disease, and kidney disease often have altered activation of these pathways, either due to underlying disease or to medications, and may be more susceptible to SARS-CoV-2 infection. Certain characteristic COVID-associated skin, sensory, and central nervous system manifestations may also be linked to viral activation of the RAAS, complement, coagulation, and KKS pathways. Pharmacological interventions that target molecules along these pathways may be useful in mitigating symptoms and preventing organ or tissue damage. While effective anti-viral therapies are critically needed, further study of these pathways may identify effective adjunctive treatments and patients most likely to benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.